Prof. Cheng Dong is an Associate Vice President for Mainland Research Advancement and a Chair Professor of Cell Engineering and Immunomedicine at Hong Kong Polytechnic University. He obtained a BS degree from Shanghai Jiao Tong University, China; he then received his MS/MPhil/PhD degrees from Columbia University, USA. He was a Distinguished Professor and Department Head of Biomedical Engineering at Penn State University in USA, before moving to Hong Kong in 2023. Prof. Dong is now a Fellow of 3 major professional organizations, including the Biomedical Engineering Society (BMES), the American Institute for Medical and Biological Engineering (AIMBE), and the International Academy of Medical and Biological Engineering (IAMBE). He has received several prestigious awards, including the Faculty Career Award from the US National Science Foundation; Faculty Research Award from the American Cancer Society; Y.C. Fung Investigator Award from the American Society of Mechanical Engineers (ASME); the Melville Medal and Best Journal Paper Award from ASME; and the Harold Lamport Young Investigator Award from BMES. The current focus of Professor Dong's research is on cell engineering and adaptive immunotherapies, using chimeric antigen receptor (CAR) immune cell-mediated nanoparticle, drug, antibody or miRNA deliveries that target either brain tumors across the blood-brain barrier or inflammatory responses in regenerative tissues.
Prof. Yun Chang is an Assistant Professor at the Department
of Biomedical Engineering, The Hong Kong Polytechnic University. He received
his bachelor’s degree from Jilin University (2013) and his Ph.D. from the
Changchun Institute of Applied Chemistry (CIAC), Chinese Academy of Sciences
(2019). He then conducted a Postdoctoral Research Fellow at Purdue University
(2019–2024). He joined The Hong Kong Polytechnic University in 2024. His
research interests focus on gene editing and the targeted differentiation of
human pluripotent stem cells, in conjunction with the application of
intelligent, functionalized biomaterials for disease immunotherapy.
